Patents by Inventor Suzanne Ross Kesten

Suzanne Ross Kesten has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biaryl ether urea compounds
    Patent number: 8044052
    Abstract: The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof; processes for the preparation of the compounds; intermediates used in the preparation of the compounds; compositions containing the compounds; and uses of the compounds in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: October 25, 2011
    Assignee: Pfizer Inc.
    Inventors: Lorraine Kathleen Fay, Douglas S. Johnson, Suzanne Ross Kesten, Scott E. Lazerwith, Mark Anthony Morris, Cory Michael Stiff, Marvin Jay Meyers, Lijuan Jane Wang
  • Biaryl Ether Urea Compounds
    Publication number: 20080261941
    Abstract: The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof; processes for the preparation of the compounds; intermediates used in the preparation of the compounds; compositions containing the compounds; and uses of the compounds in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity.
    Type: Application
    Filed: October 18, 2007
    Publication date: October 23, 2008
    Inventors: Lorraine Kathleen FAY, Douglas S. Johnson, Suzanne Ross Kesten, Scott E. Lazerwith, Mark Anthony Morris, Cory Michael Stiff, Marvin Jay Meyers, Lijuan Jane Wang
  • Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
    Patent number: 6809119
    Abstract: The invention relates to BCAT inhibitors and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, neuropathic pain, Parkinson's disease, diabetic retinopathy, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.
    Type: Grant
    Filed: November 26, 2002
    Date of Patent: October 26, 2004
    Assignee: Warner-Lambert Company LLC
    Inventors: Lain-Yen Hu, Suzanne Ross Kesten, Huangshu Lei, Todd Robert Ryder, David Juergen Wustrow
  • Bombesin antagonists
    Publication number: 20040063643
    Abstract: Compounds of formula (I): 1
    Type: Application
    Filed: April 28, 2003
    Publication date: April 1, 2004
    Applicant: Pfizer Inc.
    Inventors: Michael Higginbottom, Suzanne Ross Kesten, Russell Andrew Lewthwaite, Martyn Clive Pritchard, David James Rawson, Robert Michael Schelkun, Po-Wai Yuen
  • Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
    Publication number: 20030149110
    Abstract: The invention relates to BCAT inhibitors and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, neuropathic pain, Parkinson's disease, diabetic retinopathy, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.
    Type: Application
    Filed: November 26, 2002
    Publication date: August 7, 2003
    Inventors: Lain-Yen Hu, Suzanne Ross Kesten, Huangshu Lei, Todd Robert Ryder, David Juergen Wustrow
  • 4-Benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective NMDA receptor antagonists
    Patent number: 6284774
    Abstract: Novel 4-Benzyl piperidine alkylsulfoxide heterocycles are disclosed and their use as subtype selective NMDA receptor antagonists, particularly for the treatment of Parkinson's disease, most preferably in combination with L-DOPA.
    Type: Grant
    Filed: October 31, 2000
    Date of Patent: September 4, 2001
    Assignee: Warner-Lambert Company
    Inventors: Jonathan L. Wright, Suzanne Ross Kesten, Ravindra B. Upasani, Nancy C. Lan
  • Compounds and method of treating psychosis and schizophrenia
    Patent number: 6020364
    Abstract: This invention relates to compounds that are antagonists of dopamine D4 receptors, and to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4 receptors.
    Type: Grant
    Filed: February 22, 1999
    Date of Patent: February 1, 2000
    Assignee: Warner-Lambert Company
    Inventors: David Thomas Connor, Stephen Joseph Johnson, Suzanne Ross Kesten, Steven Robert Miller, Paul Charles Unangst, Lawrence David Wise
  • Dopamine D4 receptor antagonists
    Patent number: 5945421
    Abstract: This invention relates to compounds that are antagonists of dopamine D4 receptors, to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4 receptors, and to pharmaceutically acceptable compositions that contain a dopamine D4 receptor antagonist.
    Type: Grant
    Filed: August 11, 1997
    Date of Patent: August 31, 1999
    Assignee: Warner-Lambert Company
    Inventors: Thomas Richard Belliotti, Clifton John Blankley, Suzanne Ross Kesten, Lawrence David Wise, David Juergen Wustrow
  • Coumarin dopamine D4 receptor antagonists
    Patent number: 5922719
    Abstract: This invention relates to compounds that are antagonists of dopamine D4 receptors, to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4 receptors, and to pharmaceutically acceptable compositions that contain a dopamine D4 receptor antagonist.
    Type: Grant
    Filed: August 11, 1997
    Date of Patent: July 13, 1999
    Assignee: Warner-Lambert Company
    Inventors: Stephen Joseph Johnson, Suzanne Ross Kesten, Lawrence David Wise, David Juergen Wustrow
  • Compounds and method of treating psychosis and schizophrenia
    Patent number: 5916914
    Abstract: This invention relates to compounds that are antagonists of dopamine D4 receptors, and to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4 receptors.
    Type: Grant
    Filed: August 8, 1997
    Date of Patent: June 29, 1999
    Assignee: Warner-Lambert Company
    Inventors: David Thomas Connor, Stephen Joseph Johnson, Suzanne Ross Kesten, Steven Robert Miller, Paul Charles Unangst, Lawrence David Wise
  • Tetrahydroquinoxaline dopamine D4 receptor antagonists
    Patent number: 5885994
    Abstract: This invention relates to compounds that are antagonists of dopamine D4 receptors having Formula I below ##STR1## This invention also relates to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4 receptors, and to pharmaceutically acceptable compositions that contain a dopamine D4 receptor antagonist.
    Type: Grant
    Filed: March 5, 1998
    Date of Patent: March 23, 1999
    Assignee: Warner-Lambert Company
    Inventors: Shelly Ann Glase, Suzanne Ross Kesten